This page shows the latest Dermavant news and features for those working in and with pharma, biotech and healthcare.
Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.
Psoriasis and atopic dermatitis (eczema) candidate tapinarof is being transferred to Roivant Sciences group company Dermavant in return for £150m upfront and another £100m in the offing if it meets development
Roivant - the holding company for subsidiaries Axovant, Myovant, Dermavant, Enzyvant and just-launched urology specialist Urovant - said the cash injection will be used to launch new subsidiaries "within and beyond the
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Dermavant Sciences, a biopharmaceutical company focused on delivering therapies for dermatologic conditions, has bolstered its executive team with the addition of four new hires. ... Peterson, who previously worked at Sienna Biopharmaceuticals as its
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...